Sagimet Biosciences Doses First Patient In AURORA, Pivotal U.S. Phase 3 Clinical Trial Of Denifanstat In Adults With Moderate To Severe Acne

Loading news article.

Sagimet Biosciences Doses First Patient In AURORA, Pivotal U.S. Phase 3 Clinical Trial Of Denifanstat In Adults With Moderate To Severe Acne | WAPE

Article summary